ArticleCancer research communications2023

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.

Josep Tabernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.